ArticleNature chemical biology2019
p63 is a cereblon substrate involved in thalidomide teratogenicity.
Article in Nature chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 134 citations in OpenAlex.
- Phosphoinositides and inositol phosphates as molecular glues.FEBS letters · 2026Review
- Safety considerations for cereblon-recruiting targeted protein degraders.Nature reviews. Drug discovery · 2026Review
- Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer.Oncology research · 2026Review
- A method for the detection and enrichment of endogenous cereblon substrates.Cell chemical biology · 2025Article
- Differential substrate degradation by super-degron: EGFP in wild-type mouse cells, PD-1 requires CRBN humanization.iScience · 2025Article
- Targeted protein degradation for cancer therapy.Nature reviews. Cancer · 2025Review
- Thalidomide-induced limb malformations: an update and reevaluation.Archives of toxicology · 2025Review
- A method for the detection and enrichment of endogenous cereblon substrates.bioRxiv : the preprint server for biology · 2025Article
- Article
- Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation.Journal of hematology & oncology · 2024Article
- Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs inHeliyon · 2024Article
- The CBEMBO molecular medicine · 2024Article
- Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.Nature communications · 2024Article
- Integrative Role of the SALL4 Gene: From Thalidomide Embryopathy to Genetic Defects of the Upper Limb, Internal Organs, Cerebral Midline, and Pituitary.Hormone research in paediatrics · 2024Review
- Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations.The Journal of hand surgery, European volume · 2023Review
- Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.Nature communications · 2023Article
- A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.International journal of molecular sciences · 2023Article
- Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.Inflammopharmacology · 2023Review
- Delivering on the promise of protein degraders.Nature reviews. Drug discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple pharmacological activities, including teratogenic and antimyeloma activities. CRBN functions as a substrate receptor of the E3 ubiquitin ligase CRL4, whose substrate specificity is modulated by thalidomide and its analogs. Although a number of CRL4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.